一分钟看懂
这是一项关于腺癌的II 期 / III 期研究，登记的药物或干预包括Pumitamig；Folfox；Capox；Nivolumab，当前状态为招募中。登记地点显示中国北京、福州、广州、南宁等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Pumitamig；Folfox；Capox；Nivolumab · II 期 / III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出7项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer hospital · 北京
- Fujian Cancer Hospital · 福州
- Local Institution - 0232 · 广州
- The Sixth Affiliated Hospital of Sun Yat-sen University · 广州
- Guangxi Medical University Affiliated Tumor Hospital · 南宁
- Local Institution - 0237 · 哈尔滨
- Local Institution - 0282 · Weihui
- Local Institution - 0249 · 郑州
- Local Institution - 0279 · 武汉
- Local Institution - 0292 · 长沙
- Local Institution - 0256 · 南京
- Local Institution - 0440 · 扬州
- Local Institution - 0409 · 南昌
- Local Institution - 0244 · 沈阳
- Local Institution - 0273 · 济南
- Shanghai East Hospital · 上海
- Local Institution - 0243 · 太原
- Local Institution - 0260 · 成都
- Local Institution - 0248 · 天津
- Local Institution - 0408 · 杭州
- Local Institution - 0252 · 杭州
- Local Institution - 0269 · 上海
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Participants must be previously untreated with systemic treatment for advanced/metastatic disease, histologically or cytologically confirmed advanced or metastatic gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJC) or distal esophageal adenocarcinoma (EAC). GEJ involvement can be confirmed via biopsy, endoscopy, or imaging.
- * Participants must have a documented programmed cell death-(ligand)1 (PD-L1) ≥ 1 or \< 1 status for Phase 2, and document PD-L1 ≥ 1 status for the Phase 3 part of the study.
- * Participants must have documented human epidermal growth factor receptor 2 (HER2)-negative cancer, as determined according to local guidelines.
- * Participants must have measurable disease as defined by RECIST v1.1.
- Exclusion Criteria
- * Participants must not have untreated known central nervous system (CNS) metastases.
- * Participants must not have significant cardiovascular disease, such as myocardial infarction, unstable angina, arterial thrombosis, cerebrovascular accident within 6 months prior to randomization, uncontrolled hypertension (≥ 160 systolic, ≥ 100 diastolic mm Hg) despite optimal medical management, or congenital long QT syndrome.
- * Participants must not have evidence of major coagulation disorders (eg, hemophilia).
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07221149；登记信息更新于 2026-09-30；本站同步于 2026-10-08。